Research Reports Coverage on Biotech Stocks -- Idera Pharma, bluebird bio, Corcept Therapeutics, and PhaseRx

NEW YORK, December 16, 2016 /PRNewswire/ --

Stock-Callers.com has lined up four Biotech equities ahead of today's trading session: Idera Pharmaceuticals Inc. (NASDAQ: IDRA), bluebird bio Inc. (NASDAQ: BLUE), Corcept Therapeutics Inc. (NASDAQ: CORT), and PhaseRx Inc. (NASDAQ: PZRX). These stocks belong to the Healthcare sector which was moderately higher in late-afternoon trade on Thursday, December 15^th, 2016. As per an article on NASDAQ, the NYSE Health Care Index rose about 0.5%, while shares of health care companies in the S&P 500 also climbed about 0.6% as a group, on Thursday. These stocks research reports can be downloaded now by simply registering for free at:

http://stock-callers.com/registration

Idera Pharma 

On Thursday, shares in Cambridge, Massachusetts-based Idera Pharmaceuticals Inc. recorded a trading volume of 696,234 shares. The stock ended the session 2.45% lower at $1.59. The Company's shares are trading 9.79% below their 50-day moving average. Moreover, shares of Idera Pharma, which focuses on the discovery, development, and commercialization of therapeutics for oncology and rare diseases in the US, have a Relative Strength Index (RSI) of 42.20.

On November 28^th, 2016, Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd announced that they have entered into an exclusive license and collaboration agreement granting Vivelix worldwide rights to develop and market IMO-9200, an antagonist of TLR 7, 8, and 9 for non-malignant gastrointestinal disorders. As part of the agreement, Idera has agreed to create and characterize potential back-up compounds for Vivelix. Under terms of the agreement, Idera will receive an upfront fee of $15 million. Your complete research report on IDRA can be retrieved for free at:

http://stock-callers.com/registration/?symbol=IDRA

bluebird bio 

Cambridge, Massachusetts headquartered bluebird bio Inc.'s stock closed the day 3.26% higher at $71.25 with a total trading volume of 1.02 million shares. The Company's shares have advanced 12.03% in the past month and 10.95% on an YTD basis. The stock is trading 18.54% above its 50-day moving average and 36.62% above its 200-day moving average. Additionally, shares of bluebird bio, which focuses on developing transformative gene therapies for severe genetic and rare diseases, have an RSI of 58.60.

On December 01^st, 2016, research firm Maxim Group reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $57 a share to $87 a share.

On December 15^th, 2016, bluebird bio and apceth Biopharma GmbH announced that they have entered into a strategic manufacturing agreement providing for the future European commercial production of bluebird bio's Lenti-D™ product candidate for cerebral adrenoleukodystropy and its LentiGlobin™ product candidate for transfusion-dependent β-thalassemia. This agreement follows a successful multi-year manufacturing relationship and provides bluebird bio with European commercial manufacturing capabilities, including dedicated production suites within apceth Biopharma's GMP facility. BLUE free report is just a click away at:

http://stock-callers.com/registration/?symbol=BLUE

Corcept Therapeutics 

Shares in California headquartered Corcept Therapeutics Inc. recorded a trading volume of 869,897 shares, which was higher than their three months average volume of 653,110 shares. The stock ended yesterday's trading session 2.90% higher at $8.51. The Company's shares have surged 47.74% in the previous three months and 70.88% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 8.40% and 42.51%, respectively. Furthermore, shares of Corcept Therapeutics, which engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the US, have an RSI of 55.42.

On December 10^th, 2016, Corcept Therapeutics released efficacy data from its Phase 1/2 trial of mifepristone to treat patients with metastatic (TNBC). This open-label trial was designed to investigate whether the addition of mifepristone enhances the effect of eribulin (Halaven®) in patients with TNBC whose tumors express GR, one of the receptors to which mifepristone binds. The trial studied 21 patients with GR positive tumors, one with a GR negative tumor and one whose GR status is not known. Efficacy results obtained using the Response Evaluation Criteria in Solid Tumors showed that, 4 of these patients exhibited a partial response, defined as a 30% or greater reduction in tumor size, 8 had stable disease, and 11 had progressive disease. Sign up for your complimentary research report on CORT at:

http://stock-callers.com/registration/?symbol=CORT

PhaseRx 

Seattle, Washington headquartered PhaseRx Inc.'s stock finished Thursday's session 7.74% lower at $1.43 with a total trading volume of 88,989 shares. The Company's shares have advanced 45.16% in the last one month. The stock is trading below its 50-day moving average by 9.73%. Additionally, shares of PhaseRx, which engages in developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children, have an RSI of 46.53.

On November 28^th, 2016, PhaseRx announced that its lead candidate, PRX-OTC, which is being developed for the treatment of ornithine transcarbamylase deficiency, has received orphan drug designation by the US Food and Drug Administration. Register for free on Stock-Callers.com and download the latest research report on PZRX at:

http://stock-callers.com/registration/?symbol=PZRX

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA